• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Abbott Laboratories

Abbott Laboratories

Abbott Laboratories ABT 3 Star

Last Price$46.85Day Change (%)-0.32%
Open Price$47.02Day Change ($)-0.15
Day Range46.78–47.2152-Week Range38.25–48.62

As of Tue 5/5/2015 6:30:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Top 10 Buys and Sells by the Ultimate Stock-Pickers

    A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

  2. Research and Markets: Global Home Healthcare Global Market 2015 - Forecast to 2020

    Research and Markets: Global Home Healthcare Global Market 2015 - Forecast to 2020

  3. Diversifying in a Shrinking World

    Simple formulas for foreign exposure lose luster.

  4. Neos Therapeutics, Inc. Appoints Thomas P. McDonnell As Chief Commercial Officer

    Neos Therapeutics, Inc. Appoints Thomas P. McDonnell As Chief Commercial Officer

  5. Makers of Baby Formula Press Their Case on WIC Program

    Makers of Baby Formula Press Their Case on WIC Program

  6. AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

    AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

  7. The Rise of the 'Stichting,' an Obscure Takeover Defense

    The Rise of the 'Stichting,' an Obscure Takeover Defense

  8. U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

    U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

  9. Research and Markets: Abbott Diagnostics: Company Profile 2015

    Research and Markets: Abbott Diagnostics: Company Profile 2015

  10. AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan

    AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.